{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:20:18Z","timestamp":1791346818372,"version":"4.3.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2024,1,16]]},"abstract":"<jats:p>Background: Alzheimer\u2019s disease (AD) and related dementias are progressive neurological disorders with stage-specific clinical features and challenges. An important knowledge gap is the \u201cwindow of time\u201d within which patients transition from mild cognitive impairment or mild AD to moderate or severe AD. Better characterization\/establishment of transition times would help clinicians initiating treatments, including anti-amyloid therapy. Objective: To describe cognitive test score-based AD stage transitions in Veterans with AD in the US Veterans Affairs Healthcare System (VAHS). Methods: This retrospective analysis (2010\u20132019) identified Veterans with AD from the VAHS Electronic Health Record (EHR) notes. AD stage was based on Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), or Saint Louis University Mental Status (SLUMS) Examination scores in the EHR. Results: We identified 296,519 Veterans with cognitive test-based AD staging. Over the 10-year study, the proportion of veterans with MMSE scores declined from 24.9% to 9.5% while those with SLUMS rose from 9.0% to 17.8%; and MoCA rose from 5.0% to 25.4%. The average forward transition times between each stage were approximately 2\u20134 years, whether assessed by MMSE, MoCA, or SLUMS. Conclusion: The average transition time for cognitive test-based assessments of initial cognitive decline, early-stage AD, and moderate\/severe AD in the VAHS is 2\u20134 years. In view of the short window for introducing disease-modifying therapy and the significant benefits of early treatment of AD, our data suggest a critical need for treatment guidelines in the management of AD.<\/jats:p>","DOI":"10.3233\/jad-230850","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T10:58:46Z","timestamp":1703242726000},"page":"687-695","source":"Crossref","is-referenced-by-count":1,"title":["Alzheimer\u2019s Disease Stage Transitions Among United States Veterans"],"prefix":"10.1177","volume":"97","author":[{"given":"Peter","family":"Morin","sequence":"first","affiliation":[{"name":"Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron J.","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Geriatric Research Education and Clinical Center, Bedford VA Healthcare System, Bedford, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyang","family":"Li","sequence":"additional","affiliation":[{"name":"Geriatric Research Education and Clinical Center, Bedford VA Healthcare System, Bedford, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Epidemiology, Data Science Core, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Berlowitz","sequence":"additional","affiliation":[{"name":"Department of Public Health, Zuckerberg College of Health Sciences, University of Massachusetts Lowell, Lowell, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Zhang","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease and Brain Health, EisaiInc., Nutley, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Abbas","family":"Tahami Monfared","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease and Brain Health, EisaiInc., Nutley, NJ, USA"},{"name":"Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanwu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease and Brain Health, EisaiInc., Nutley, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Xia","sequence":"additional","affiliation":[{"name":"Geriatric Research Education and Clinical Center, Bedford VA Healthcare System, Bedford, MA, USA"},{"name":"Department of Pharmacology, Physiology and Biophysics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA"},{"name":"Department of Biological Sciences, Kennedy College of Science, University of Massachusetts Lowell, Lowell, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-230850_ref1","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"10.3233\/JAD-230850_ref2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","article-title":"Meaningful benefits: Aframework to assess disease-modifying therapies in preclinical andearly Alzheimer\u2019s disease","volume":"14","author":"Assunc\u00e3o","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-230850_ref3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","article-title":"Aducanumab: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.3233\/JAD-230850_ref4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-230850_ref5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.JGP.0000192478.82189.a8","article-title":"Mapping scores onto stages: Mini-mental state examination and clinical dementia rating","volume":"14","author":"Perneczky","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-230850_ref9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s40120-022-00379-z","article-title":"Clinical staging of Alzheimer\u2019s disease: Concordance of subjective and objective assessments in the Veteran\u2019s Affairs Healthcare System","volume":"11","author":"Morin","year":"2022","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-230850_ref10","first-page":"398","article-title":"Aducanumab: Appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-230850_ref11","first-page":"362","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.3233\/JAD-230850_ref12","first-page":"457","article-title":"VA Informatics and Computing Infrastructure","volume":"13","author":"VINCI","year":"2023","journal-title":"VA HSR RES"},{"key":"10.3233\/JAD-230850_ref13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.trci.2019.06.005","article-title":"Disease severity and minimal clinically important differencesin clinical outcome assessments for Alzheimer\u2019s disease clinicaltrials","volume":"5","author":"Andrews","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-230850_ref14","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s40120-023-00540-2","article-title":"Rule-based identification of individuals with mild cognitive impairment or Alzheimer\u2019s disease using clinical notes from the United States Veterans Affairs Healthcare System","volume":"12","author":"Aguilar","year":"2023","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-230850_ref15","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s40120-022-00393-1","article-title":"A simulation model to evaluate the potential impact of disease-modifying treatments on burden of illness in Alzheimer\u2019s disease","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-230850_ref16","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","article-title":"The potential economic value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-230850_ref17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/fhep-2014-0013","article-title":"The value of delaying Alzheimer\u2019s disease onset","volume":"18","author":"Zissimopoulos","year":"2014","journal-title":"Forum Health Econ Policy"},{"key":"10.3233\/JAD-230850_ref18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/archneur.58.3.449","article-title":"A method for estimating progression rates in Alzheimer disease","volume":"58","author":"Doody","year":"2001","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-230850_ref19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12877-015-0103-3","article-title":"Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults","volume":"15","author":"Trzepacz","year":"2015","journal-title":"BMC Geriatr"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-230850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:09Z","timestamp":1777370949000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-230850"}},"subtitle":[],"editor":[{"given":"Nicole","family":"Rogus-Pulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":16,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-230850","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}